



Execution of an Agreement to Terminate the Commercialization Agreement with SUSMED Co., Ltd. for a Digital Therapeutic Application for Insomnia

OSAKA, Japan, August 26, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that we have agreed with SUSMED Co., Ltd. (Head Office: Tokyo, Japan; President and CEO: Taro Ueno) to terminate, as of today, the "Commercialization Agreement for a Digital Therapeutic Application for Insomnia"¹ (hereafter the "Agreement") concluded between the two companies.

Since the conclusion of the Agreement, we have advanced our efforts under the Agreement. Following repeated discussions, we have concluded an agreement to terminate the Agreement today. Meanwhile, the importance of Shionogi's commitment to the sleep disorder area remains unchanged.

Leveraging our strengths and expertise, Shionogi will continue to promote a range of initiatives, including not only the provision of therapeutics but also disease awareness and research and development, so as to contribute to the treatment and the improvement in quality of life (QOL) of patients living with insomnia.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>

Reference List:

1. Press Release, December 27, 2021:
[SHIONOGI Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic App for Insomnia](#)